Braun Stacey Associates’s Ascendis Pharma A/S ASND Stock Holding History

Braun Stacey Associates’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$30.4M	Buy	133,224 +542	+0.4%	+$137K	0.87%	41
2026 Q2	$35.4M	Buy	132,682 +1,690	+1%	+$395K	1%	32
2026 Q1	$30M	Buy	130,992 +11,897	+10%	+$2.67M	1%	35
2025 Q4	$25.4M	Buy	119,095 +25,148	+27%	+$5.19M	0.82%	47
2025 Q3	$18.7M	Buy	+93,947	New	+$17.5M	0.61%	74

Other funds holding ASND

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $144B AUM 22.91% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

SEI Investments Oaks, Pennsylvania $113B AUM 26.61% 1-Year Est. Return

ARS Investment Partners New York $2.23B AUM 74.02% 1-Year Est. Return

Braun Stacey Associates's ASND Position: Q3 2026 in Review

Braun Stacey Associates increased its Ascendis Pharma A/S (ASND) stake by 0.41% in Q3 2026, buying an estimated $137K and bringing the position to 133,224 shares worth $30.4M. The position accounts for 0.87% of the portfolio, ranked #41.

Braun Stacey Associates first reported a position in ASND in Q3 2025 and has held it in 5 quarters since. The position peaked at $35.4M in Q2 2026. 171 funds tracked by Wall St. Rank hold ASND as of Q3 2026.

Braun Stacey Associates held 133,224 shares of Ascendis Pharma A/S worth $30.4M as of Q3 2026.
Braun Stacey Associates bought 542 Ascendis Pharma A/S shares in Q3 2026, an estimated $137K.
Ascendis Pharma A/S made up 0.87% of Braun Stacey Associates's portfolio in Q3 2026, its #41 holding.
Braun Stacey Associates first reported a position in Ascendis Pharma A/S in Q3 2025 and has held it in 5 quarters since.
Braun Stacey Associates's Ascendis Pharma A/S position peaked at $35.4M in Q2 2026.
171 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q3 2026.

Based on Braun Stacey Associates's 13F filing for Q3 2026, filed 19 Oct 2026.